Diabetes & metabolic syndromeAgedFemaleHumansMaleMiddle Aged
Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.
José Seijas-Amigo, Ángel Salgado-Barreira, Rosana Castelo-Dominguez, María Teresa Pérez-Álvarez, Belén Ponce-Piñón, Marlén Fernández-Silva, Marta Rodríguez-Barreiro, Mercedes Pereira-Pía, Jose Manuel Iglesias-Moreno, Mar Gago-García, Raquel Montáns-García, Agustina Fernandez-Perez, Dolores Fraga-Gayoso, Montse Fernandez-Montenegro, Beatriz Riveiro-Barciela
Published: 202510.1016/j.dsx.2025.103312
Abstract
AIMS: Patients with Type 2 diabetes mellitus face elevated cardiovascular risk. We assessed the effect of GLP-1 receptor agonists on 10-year CVR in a primary prevention cohort. METHODS: In this 44-week prospective, non-randomized study, 135 patients…
Preview only. Read the full abstract at the source